Midkine Role With Deregulated Oxidative and Immune Milieu in Induction of Preeclampsia

Pre-Eclampsia Clinical Trial

Official title:

Midkine Interplays With Oxidative Stress and Inflammatory Milieu to Induce Preeclampsia in Normotensive Pregnant Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06329284
• Other study ID #: RC 31.1.2024
• Status: Completed
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: December 15, 2023

Study information

• Verified date: March 2024
• Source: Benha University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Preeclampsia (PE) is a hypertensive pregnancy-related disorder that endangers maternal and fetal outcomes and accounts for 9-10% of maternal mortalities with its early-onset phenotype is the most dangerous, but its etiology is still not fully elucidated.

Midkine (MDK) is a multifunctional protein that plays a unique role in the development of hypertension (HTN), via its proatherogenic effect and induction of overexpression of angiotensin converting enzyme. Oxidative stress (OS) upregulates the expression of MDK and MDK induces propagation of neoangiogenesis and acts as chemotactic for neutrophils.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: December 15, 2023
• Est. primary completion date: September 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 21 Years to 50 Years

Eligibility

Inclusion Criteria:

• Newly pregnant normotensive (NT) women with singleton fetus;

• Free of the Exclusion Criteria.

Exclusion Criteria:

• Women with history of complicated pregnancy;

• Had manifest essential hypertension, Diabetes Mellitus or chronic kidney diseases;

• Had multiple gestational sacs, morbid obesity with Body Mass Index at time of pregnancy diagnosis over 35 kg/m2;

• Had genetic disorders, coagulopathy, autoimmune diseases or maintained on immunosuppressive therapy.

Related Conditions & MeSH terms

• Eclampsia
• Pre-Eclampsia

Intervention

Diagnostic Test:
• ELISA
ELISA estimation of serum Midkine, tumor necrosis factor Alfa, superoxide dismutase, malondialdehyde, placental growth factor and placental soluble fms-like tyrosine kinase 1

Locations

Country	Name	City	State
Egypt	Banha University	Banha	El- Qalyobia

Sponsors (1)

Lead Sponsor	Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severity of Pre-Eclampsia (PE)	Correlation between Serum midkine levels and blood pressure measurements	8 months